메뉴 건너뛰기




Volumn 21, Issue 5, 2013, Pages 1487-1495

The multinational association for supportive care in cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients

Author keywords

Febrile neutropenia; Low risk identification; MASCC score

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; CEFEPIME; CEFTRIAXONE; CIPROFLOXACIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMIPENEM; INTERLEUKIN 10; INTERLEUKIN 3; INTERLEUKIN 6; INTERLEUKIN 8; MANNOSE BINDING LECTIN; MEROPENEM; MOXIFLOXACIN; PENTRAXIN 3; PIPERACILLIN; POLYPEPTIDE ANTIBIOTIC AGENT; TICARCILLIN;

EID: 84878400408     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-013-1758-y     Document Type: Review
Times cited : (101)

References (70)
  • 1
    • 0013877409 scopus 로고    scopus 로고
    • Quantitative relationship between circulating leukocytes and infection in patients with acute leukemia
    • Bodey GP, Buckley M, Sathe YS et al (1996) Quantitative relationship between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328-340
    • (1996) Ann Intern Med , vol.64 , pp. 328-340
    • Bodey, G.P.1    Buckley, M.2    Sathe, Y.S.3
  • 2
    • 0015221860 scopus 로고
    • Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia
    • 10.1056/NEJM197105132841904
    • Schimpff S, Satterlee W, Young VM et al (1971) Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 284:161-165
    • (1971) N Engl J Med , vol.284 , pp. 161-165
    • Schimpff, S.1    Satterlee, W.2    Young, V.M.3
  • 3
    • 0020730359 scopus 로고
    • Empiric treatment of infections in neutropenic patients with cancer
    • 6342096 10.1093/clinids/5.Supplement-1.S21
    • Klastersky J (1983) Empiric treatment of infections in neutropenic patients with cancer. Rev Infect Dis 5:S21-S23
    • (1983) Rev Infect Dis , vol.5
    • Klastersky, J.1
  • 4
    • 0023551772 scopus 로고
    • Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia
    • The EORTC International Antimicrobial Therapy Cooperative Group
    • The EORTC International Antimicrobial Therapy Cooperative Group (1978) Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 317:1692-1698
    • (1978) N Engl J Med , vol.317 , pp. 1692-1698
  • 5
    • 0026599442 scopus 로고
    • Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule
    • 1732432 1:STN:280:DyaK387itF2ntw%3D%3D
    • Talcott JA, Siegel RD, Finberg R et al (1992) Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 10:316-322
    • (1992) J Clin Oncol , vol.10 , pp. 316-322
    • Talcott, J.A.1    Siegel, R.D.2    Finberg, R.3
  • 6
    • 0027976188 scopus 로고
    • Home antibiotic-therapy for low-risk cancer patients with fever and neutropenia - A pilot-study of 30 patients based on a validated prediction rule
    • 8270967 1:STN:280:DyaK2c%2Fps1Sntg%3D%3D
    • Talcott JA, Whalen A, Clark J et al (1994) Home antibiotic-therapy for low-risk cancer patients with fever and neutropenia-a pilot-study of 30 patients based on a validated prediction rule. J Clin Oncol 12:107-114
    • (1994) J Clin Oncol , vol.12 , pp. 107-114
    • Talcott, J.A.1    Whalen, A.2    Clark, J.3
  • 7
    • 0033614926 scopus 로고    scopus 로고
    • Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy
    • 10.1056/NEJM199907293410502
    • Kern WV, Cometta A, De Bock R et al (1999) Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med 314:312-318
    • (1999) N Engl J Med , vol.314 , pp. 312-318
    • Kern, W.V.1    Cometta, A.2    De Bock, R.3
  • 8
    • 0033615008 scopus 로고    scopus 로고
    • A double blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy
    • 10423464 10.1056/NEJM199907293410501 1:CAS:528:DyaK1MXltVKgs7w%3D
    • Freifeld A, Marchigiani D, Walsh T et al (1999) A double blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 341:305-3011
    • (1999) N Engl J Med , vol.341 , pp. 305-3011
    • Freifeld, A.1    Marchigiani, D.2    Walsh, T.3
  • 9
    • 0033904644 scopus 로고    scopus 로고
    • The multinational association for supportive care in cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients
    • 10944139 1:STN:280:DC%2BD3cvivFCrsg%3D%3D
    • Klastersky J, Paesmans M, Rubenstein EB et al (2000) The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038-3051
    • (2000) J Clin Oncol , vol.18 , pp. 3038-3051
    • Klastersky, J.1    Paesmans, M.2    Rubenstein, E.B.3
  • 10
    • 77954338016 scopus 로고    scopus 로고
    • Management of febrile neutropenia: ESMO Clinical Practice Guidelines
    • 10.1093/annonc/mdq196
    • Naurois J, Novitzky-Basso I, Gill JM et al (2010) Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol 21:252-256
    • (2010) Ann Oncol , vol.21 , pp. 252-256
    • Naurois, J.1    Novitzky-Basso, I.2    Gill, J.M.3
  • 11
    • 0037087226 scopus 로고    scopus 로고
    • 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer
    • 11850858 10.1086/339215
    • Hughes WT, Amstrong D, Bodey GP et al (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730-751
    • (2002) Clin Infect Dis , vol.34 , pp. 730-751
    • Hughes, W.T.1    Amstrong, D.2    Bodey, G.P.3
  • 12
    • 79951816939 scopus 로고    scopus 로고
    • Executive summary: Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by infectious diseases society of America
    • 21258094 10.1093/cid/cir073
    • Freifeld A, Bow E, Sepkowitz K et al (2011) Executive summary: clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by infectious diseases society of America. Clin Infect Dis 52:e56-e93
    • (2011) Clin Infect Dis , vol.52
    • Freifeld, A.1    Bow, E.2    Sepkowitz, K.3
  • 13
    • 4043155814 scopus 로고    scopus 로고
    • Febrile neutropenia: A prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk index score
    • 15197637 10.1007/s00520-004-0614-5
    • Uys A, Rapoport B, Anderson R (2004) Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk index score. Support Care Cancer 12:555-560
    • (2004) Support Care Cancer , vol.12 , pp. 555-560
    • Uys, A.1    Rapoport, B.2    Anderson, R.3
  • 14
    • 33644554514 scopus 로고    scopus 로고
    • The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies
    • 16461306
    • Cherif H, Johansson E, Björkholm M et al (2006) The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies. Haematologica 91:215-222
    • (2006) Haematologica , vol.91 , pp. 215-222
    • Cherif, H.1    Johansson, E.2    Björkholm, M.3
  • 15
    • 44449120171 scopus 로고    scopus 로고
    • Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients
    • 18437382 10.1007/s00277-008-0487-7
    • Baskaran ND, Gan GG, Adeeba K (2008) Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients. Ann Hematol 87:563-569
    • (2008) Ann Hematol , vol.87 , pp. 563-569
    • Baskaran, N.D.1    Gan, G.G.2    Adeeba, K.3
  • 16
    • 80052448364 scopus 로고    scopus 로고
    • Prediction of outcome in cancer patients with febrile neutropenia: A prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network
    • 10.1007/s00520-010-0993-8
    • Pun Hui E, Leung KS, Poon T et al (2011) Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network. Support Care Cancer 19:1625-1635
    • (2011) Support Care Cancer , vol.19 , pp. 1625-1635
    • Pun Hui, E.1    Leung, K.S.2    Poon, T.3
  • 17
    • 80052023969 scopus 로고    scopus 로고
    • Prognostic evaluation of febrile neutropaenia in apparently stable adult cancer patient
    • 21811253 10.1038/bjc.2011.284 1:STN:280:DC%2BC3Mjot1Oqtw%3D%3D
    • Carmona-Bayonas A, Gómez J, González-Billalabeitia E et al (2011) Prognostic evaluation of febrile neutropaenia in apparently stable adult cancer patient. Br J Cancer 105:612-617
    • (2011) Br J Cancer , vol.105 , pp. 612-617
    • Carmona-Bayonas, A.1    Gómez, J.2    González-Billalabeitia, E.3
  • 18
    • 84855894765 scopus 로고    scopus 로고
    • Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer
    • 10.1186/1741-7015-10-6
    • Philips R, Wade R, Lehrnbecher T et al (2012) Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer. BMC Med 10:6
    • (2012) BMC Med , vol.10 , pp. 6
    • Philips, R.1    Wade, R.2    Lehrnbecher, T.3
  • 19
    • 80051596932 scopus 로고    scopus 로고
    • Predicting febrile neutropenic patients at low risk using the MASCC score: Does bacteremia matter?
    • 20596732 10.1007/s00520-010-0925-7
    • Paesmans M, Klastersky J, Maertens J et al (2011) Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter? Support Care Cancer 19:1001-1008
    • (2011) Support Care Cancer , vol.19 , pp. 1001-1008
    • Paesmans, M.1    Klastersky, J.2    Maertens, J.3
  • 20
    • 0036234739 scopus 로고    scopus 로고
    • Monotherapy or aminoglycoside containing combinations for empirical antibiotic treatment of febrile neutropenia patients: A meta-analysis
    • 1:CAS:528:DC%2BD38Xjtlent7w%3D
    • Furno P, Bucaneve G, Del Favero A (2002) Monotherapy or aminoglycoside containing combinations for empirical antibiotic treatment of febrile neutropenia patients: a meta-analysis. Lancet 2:231-243
    • (2002) Lancet , vol.2 , pp. 231-243
    • Furno, P.1    Bucaneve, G.2    Del Favero, A.3
  • 21
    • 43549085918 scopus 로고    scopus 로고
    • Antibiothérapie empirique lors de neutropénie febrile
    • 18578432 1:STN:280:DC%2BD1cvhtVSgsg%3D%3D
    • Kridel R, Van Delden C, Calandra T et al (2008) Antibiothérapie empirique lors de neutropénie febrile. Rev Med Suisse 4:914-919
    • (2008) Rev Med Suisse , vol.4 , pp. 914-919
    • Kridel, R.1    Van Delden, C.2    Calandra, T.3
  • 22
    • 77950162473 scopus 로고    scopus 로고
    • Antibiotic management of febrile neutropenia: Current developments and future directions
    • 20227985 1:CAS:528:DC%2BC3cXlsFSqs7o%3D
    • Mebis J, Goossens H, Berneman ZN (2010) Antibiotic management of febrile neutropenia: current developments and future directions. J Chemother 22:5-12
    • (2010) J Chemother , vol.22 , pp. 5-12
    • Mebis, J.1    Goossens, H.2    Berneman, Z.N.3
  • 23
    • 77953051426 scopus 로고    scopus 로고
    • Neutropénie fébrile chez le patient adulte atteint de tumeur solide: Revue de la littérature pour une gestion rationnelle et optimale
    • Event C, Taillade L, Spano JP et al (2010) Neutropénie fébrile chez le patient adulte atteint de tumeur solide: revue de la littérature pour une gestion rationnelle et optimale. Bull Cancer 97:547-557
    • (2010) Bull Cancer , vol.97 , pp. 547-557
    • Event, C.1    Taillade, L.2    Spano, J.P.3
  • 24
    • 79251535327 scopus 로고    scopus 로고
    • Use of empiric antimicrobial therapy in neutropenic fever
    • 21272173 10.1111/j.1445-5994.2010.02340.x 1:CAS:528:DC%2BC3MXivFWht7c%3D
    • Tam CS, O'Reilly M, Andresen D et al (2011) Use of empiric antimicrobial therapy in neutropenic fever. Intern Med J 41:90-101
    • (2011) Intern Med J , vol.41 , pp. 90-101
    • Tam, C.S.1    O'Reilly, M.2    Andresen, D.3
  • 25
    • 71349083356 scopus 로고    scopus 로고
    • Oral moxifloxacin for outpatients treatment of low-risk, febrile neutropenic patients
    • 19387695 10.1007/s00520-009-0634-2
    • Rolston K, Frisbee-Hume S, Patel S et al (2010) Oral moxifloxacin for outpatients treatment of low-risk, febrile neutropenic patients. Support Care Cancer 18:89-94
    • (2010) Support Care Cancer , vol.18 , pp. 89-94
    • Rolston, K.1    Frisbee-Hume, S.2    Patel, S.3
  • 26
    • 38049141184 scopus 로고    scopus 로고
    • Compliance with a critical pathway for the management of febrile neutropenia and impact on clinical outcomes
    • 17938926 10.1007/s00277-007-0390-7 1:STN:280:DC%2BD1c%2Fgs1yluw%3D%3D
    • Zuckermann J, Moreira L, Stoll P (2008) Compliance with a critical pathway for the management of febrile neutropenia and impact on clinical outcomes. Ann Hematol 87:139-145
    • (2008) Ann Hematol , vol.87 , pp. 139-145
    • Zuckermann, J.1    Moreira, L.2    Stoll, P.3
  • 27
    • 49349090753 scopus 로고    scopus 로고
    • Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge
    • 18197434 10.1007/s00520-007-0383-z
    • Sebban C, Dussart S, Fuhrmann C et al (2008) Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge. Support Care Cancer 16:1017-1023
    • (2008) Support Care Cancer , vol.16 , pp. 1017-1023
    • Sebban, C.1    Dussart, S.2    Fuhrmann, C.3
  • 28
    • 0042846028 scopus 로고    scopus 로고
    • Oral antibiotics with early hospital discharge compared with in-patients intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: A prospective randomized controlled single centre study
    • 12838298 10.1038/sj.bjc.6600993 1:CAS:528:DC%2BD3sXltVWms7c%3D
    • Innes HE, Smith DB, O'Reilly SM et al (2003) Oral antibiotics with early hospital discharge compared with in-patients intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomized controlled single centre study. Br J Cancer 89:43-49
    • (2003) Br J Cancer , vol.89 , pp. 43-49
    • Innes, H.E.1    Smith, D.B.2    O'Reilly, S.M.3
  • 29
    • 41849097436 scopus 로고    scopus 로고
    • Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: Feasibility and safety in routine clinical practice
    • 17899215 10.1007/s00520-007-0334-8
    • Innes H, Lim S, Hall A et al (2008) Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice. Support Care Cancer 16:485-4941
    • (2008) Support Care Cancer , vol.16 , pp. 485-4941
    • Innes, H.1    Lim, S.2    Hall, A.3
  • 30
    • 33748661910 scopus 로고    scopus 로고
    • Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications
    • 16943529 10.1200/JCO.2005.03.9909 1:CAS:528:DC%2BD28XhtVantbrP
    • Klastersky J, Paesmans M, Georgala A et al (2006) Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 24:4129-4134
    • (2006) J Clin Oncol , vol.24 , pp. 4129-4134
    • Klastersky, J.1    Paesmans, M.2    Georgala, A.3
  • 31
    • 84861097138 scopus 로고    scopus 로고
    • First-day step-down to oral outpatient treatment versus continued standard treatment in children with cancer and low-risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study
    • 10.1002/pbc.24076 22271702 10.1002/pbc.24076
    • Brack E, Bodmer N, Simon A et al (2012) First-day step-down to oral outpatient treatment versus continued standard treatment in children with cancer and low-risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study. Pediatr Blood Cancer 59(3):423-430. doi: 10.1002/pbc.24076
    • (2012) Pediatr Blood Cancer , vol.59 , Issue.3 , pp. 423-430
    • Brack, E.1    Bodmer, N.2    Simon, A.3
  • 32
    • 45249110692 scopus 로고    scopus 로고
    • Outpatient management of febrile neutropenia: Time to revise the present treatment strategy
    • 18551855 1:CAS:528:DC%2BD1cXnsVKksL8%3D
    • Carstensen M, Sorensen JB (2008) Outpatient management of febrile neutropenia: time to revise the present treatment strategy. J Support Oncol 6:199-208
    • (2008) J Support Oncol , vol.6 , pp. 199-208
    • Carstensen, M.1    Sorensen, J.B.2
  • 33
    • 79955481040 scopus 로고    scopus 로고
    • Outpatient management of cancer patients with febrile neutropenia: A systematic review and meta-analysis
    • 21363878 10.1093/annonc/mdq745 1:STN:280:DC%2BC3MbjsV2ksQ%3D%3D
    • Teuffel O, Ethier MC, Alibhal SM et al (2011) Outpatient management of cancer patients with febrile neutropenia: a systematic review and meta-analysis. Ann Oncol 22:2358-2365
    • (2011) Ann Oncol , vol.22 , pp. 2358-2365
    • Teuffel, O.1    Ethier, M.C.2    Alibhal, S.M.3
  • 34
    • 79955471557 scopus 로고    scopus 로고
    • Cost-effectiveness of outpatient treatment for febrile neutropaenia in adult cancer patients
    • 10.1038/bjc.2011.101 1:STN:280:DC%2BC3MvmvVejtA%3D%3D
    • Teuffel E, Amir, Alibhai S et al (2011) Cost-effectiveness of outpatient treatment for febrile neutropaenia in adult cancer patients. B JCancer 104:1377-1383
    • (2011) B JCancer , vol.104 , pp. 1377-1383
    • Teuffel, E.1    Amir2    Alibhai, S.3
  • 35
    • 39149137569 scopus 로고    scopus 로고
    • Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia
    • 18235119 10.1200/JCO.2007.13.8222
    • Elting L, Lu C, Escalante C et al (2008) Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol 26:606-611
    • (2008) J Clin Oncol , vol.26 , pp. 606-611
    • Elting, L.1    Lu, C.2    Escalante, C.3
  • 36
    • 80054736109 scopus 로고    scopus 로고
    • Safety of early discharge for low-risk patients with febrile neutropenia: A multicenter randomized controlled trial
    • 21931024 10.1200/JCO.2011.35.0884
    • Talcott J, Yeap B, Clark J et al (2011) Safety of early discharge for low-risk patients with febrile neutropenia: a multicenter randomized controlled trial. J Clin Oncol 29:3977-3988
    • (2011) J Clin Oncol , vol.29 , pp. 3977-3988
    • Talcott, J.1    Yeap, B.2    Clark, J.3
  • 37
    • 80054740621 scopus 로고    scopus 로고
    • Costs of home versus inpatient treatment for fever and neutropenia: Analysis of a multicenter randomized trial
    • 21931037 10.1200/JCO.2011.35.1247
    • Hendricks A, Trice Loggers E, Talcott J (2011) Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. J Clin Oncol 29:3984-3988
    • (2011) J Clin Oncol , vol.29 , pp. 3984-3988
    • Hendricks, A.1    Trice Loggers, E.2    Talcott, J.3
  • 38
    • 84868459981 scopus 로고    scopus 로고
    • Health-related quality of life anticipated with different management strategies for febrile neutropenia in adult cancer patients
    • 22350594 10.1007/s00520-012-1397-8 1:STN:280:DC%2BC38vjs1Kmuw%3D%3D
    • Teuffel O, Cheng S, Ethier M et al (2012) Health-related quality of life anticipated with different management strategies for febrile neutropenia in adult cancer patients. Support Care Cancer 20(11):2755-2764
    • (2012) Support Care Cancer , vol.20 , Issue.11 , pp. 2755-2764
    • Teuffel, O.1    Cheng, S.2    Ethier, M.3
  • 39
    • 84055200503 scopus 로고    scopus 로고
    • Parental perspectives on inpatient versus outpatient management of pediatric febrile neutropenia
    • 22194148 10.1177/1043454211418665
    • Diorio C, Martino J, Boydell K et al (2011) Parental perspectives on inpatient versus outpatient management of pediatric febrile neutropenia. J Pediatr Oncol Nurs 28:355-362
    • (2011) J Pediatr Oncol Nurs , vol.28 , pp. 355-362
    • Diorio, C.1    Martino, J.2    Boydell, K.3
  • 40
    • 84863985263 scopus 로고    scopus 로고
    • Outpatient and oral antibiotic management of low-risk febrile neutropenia are effective in children - A systematic review of prospective trials
    • 22402749 10.1007/s00520-012-1425-8 1:STN:280:DC%2BC38vlvFynuw%3D%3D
    • Manji A, Beyene J, Dupuis R et al (2012) Outpatient and oral antibiotic management of low-risk febrile neutropenia are effective in children - a systematic review of prospective trials. Support Care Cancer 20:1135-1145
    • (2012) Support Care Cancer , vol.20 , pp. 1135-1145
    • Manji, A.1    Beyene, J.2    Dupuis, R.3
  • 41
    • 84860254785 scopus 로고    scopus 로고
    • Discrete choice experiment produced estimates of acceptable risks of therapeutic options in cancer patients with febrile neutropenia
    • 22424607 10.1016/j.jclinepi.2011.11.008
    • Sung L, Alibhai S, Ethier MC et al (2012) Discrete choice experiment produced estimates of acceptable risks of therapeutic options in cancer patients with febrile neutropenia. J Clin Epidemiol 65:627-634
    • (2012) J Clin Epidemiol , vol.65 , pp. 627-634
    • Sung, L.1    Alibhai, S.2    Ethier, M.C.3
  • 42
    • 38349095054 scopus 로고    scopus 로고
    • Clinical practice patterns of managing low-risk adult febrile neutropenia during cancer chemotherapy in the USA
    • 17943327 10.1007/s00520-007-0308-x
    • Freifeld A, Sankaranarayanan J, Ullrich F et al (2008) Clinical practice patterns of managing low-risk adult febrile neutropenia during cancer chemotherapy in the USA. Support Care Cancer 16:181-191
    • (2008) Support Care Cancer , vol.16 , pp. 181-191
    • Freifeld, A.1    Sankaranarayanan, J.2    Ullrich, F.3
  • 43
    • 0027300930 scopus 로고
    • Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer
    • 8490912 10.1002/1097-0142(19930601)71:11<3640: AID- CNCR2820711128>3.0.CO;2-H 1:STN:280:DyaK3s3lvVOntw%3D%3D
    • Rubenstein EB, Rolston K, Benjamin RS et al (1993) Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 71:3640-3646
    • (1993) Cancer , vol.71 , pp. 3640-3646
    • Rubenstein, E.B.1    Rolston, K.2    Benjamin, R.S.3
  • 44
    • 34848845798 scopus 로고    scopus 로고
    • Bacteraemia in febrile neutropenic cancer patients
    • 17689933 10.1016/j.ijantimicag.2007.06.012 1:CAS:528:DC%2BD2sXhtFeitLvP
    • Klastersky J, Ameye L, Maertens et al (2007) Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents 30(Suppl 1):S51-S59
    • (2007) Int J Antimicrob Agents , vol.30 , Issue.SUPPL. 1
    • Klastersky, J.1    Ameye, L.2    Maertens3
  • 45
    • 1842831404 scopus 로고    scopus 로고
    • Patients neutropéniques fébriles à bas et haut risques
    • 10.1016/S0755-4982(04)98634-4
    • Blot F, Nitenberg G (2004) Patients neutropéniques fébriles à bas et haut risques. Presse Med 33:473-479
    • (2004) Presse Med , vol.33 , pp. 473-479
    • Blot, F.1    Nitenberg, G.2
  • 46
    • 84859057522 scopus 로고    scopus 로고
    • Management of febrile neutropenia in an acute oncology service
    • 10.1093/qjmed/hcr217 1:STN:280:DC%2BC38znsVCjtg%3D%3D
    • Sammut S, Mazhar D (2012) Management of febrile neutropenia in an acute oncology service. Q J Med 105:327-336
    • (2012) Q J Med , vol.105 , pp. 327-336
    • Sammut, S.1    Mazhar, D.2
  • 47
    • 77950952140 scopus 로고    scopus 로고
    • Febrile neutropenia in French emergency departments: Results of a prospective multicentre survey
    • 20403164 10.1186/cc8972
    • André S, Taboulet P, Elie C (2010) Febrile neutropenia in French emergency departments: results of a prospective multicentre survey. Crit Care 14:R68
    • (2010) Crit Care , vol.14
    • André, S.1    Taboulet, P.2    Elie, C.3
  • 48
    • 81755176060 scopus 로고    scopus 로고
    • Febrile neutropenia in EDs: The role of an electronic clinical practice guideline
    • 21030183 10.1016/j.ajem.2010.08.011 11, 11.e1-5
    • Lim C, Bawden J, Wing A et al (2012) Febrile neutropenia in EDs: the role of an electronic clinical practice guideline. Am J Emerg Med 30(1):5, 11, 11.e1-5
    • (2012) Am J Emerg Med , vol.30 , Issue.1
    • Lim, C.1    Bawden, J.2    Wing, A.3
  • 49
    • 0035829842 scopus 로고    scopus 로고
    • Early goal-directed therapy in the treatment of severe sepsis and septic shock
    • 11794169 10.1056/NEJMoa010307 1:STN:280:DC%2BD38%2FmsFGjtA%3D%3D
    • Rivers E, Nguyen B, Havstad S et al (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368-1377
    • (2001) N Engl J Med , vol.345 , pp. 1368-1377
    • Rivers, E.1    Nguyen, B.2    Havstad, S.3
  • 50
    • 80051596038 scopus 로고    scopus 로고
    • Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia
    • 20552376 10.1007/s00520-010-0928-4
    • Ahn S, Lee YS, Chun YH et al (2011) Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia. Support Care Cancer 19:1151-1158
    • (2011) Support Care Cancer , vol.19 , pp. 1151-1158
    • Ahn, S.1    Lee, Y.S.2    Chun, Y.H.3
  • 51
    • 84859832879 scopus 로고    scopus 로고
    • The usefulness of procalcitonin and C-reactive protein as early diagnostic markers of bacteremia in cancer patients with febrile neutropenia
    • 22022295 10.4143/crt.2011.43.3.176
    • Kim D, Lee YS, Ahn S et al (2011) The usefulness of procalcitonin and C-reactive protein as early diagnostic markers of bacteremia in cancer patients with febrile neutropenia. Cancer Res Treat 43:176-180
    • (2011) Cancer Res Treat , vol.43 , pp. 176-180
    • Kim, D.1    Lee, Y.S.2    Ahn, S.3
  • 52
    • 35348978703 scopus 로고    scopus 로고
    • Prediction of outcome in cancer patients with febrile neutropenia: Comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1β, -6 and -10
    • 10.1111/j.1365-2354.2007.00780.x 1:STN:280:DC%2BD2snitVKmtg%3D%3D
    • Uys A, Rapoport B, Meyer P et al (2007) Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1β, -6 and -10. Eur J Cancer Care (Engl) 16:475-483
    • (2007) Eur J Cancer Care (Engl) , vol.16 , pp. 475-483
    • Uys, A.1    Rapoport, B.2    Meyer, P.3
  • 53
    • 77953709282 scopus 로고    scopus 로고
    • Elevation in serum lactate at the time of febrile neutropenia (FN) in hemodynamically-stable patients with hematologic malignancies (HM) is associated with the development of septic shock within 48 h
    • 20160493 10.4161/cbt.9.8.11270 1:CAS:528:DC%2BC3cXhtlKgtrbE
    • Mato A, Luger S, Heitjan D et al (2010) Elevation in serum lactate at the time of febrile neutropenia (FN) in hemodynamically-stable patients with hematologic malignancies (HM) is associated with the development of septic shock within 48 h. Cancer Biol Ther 9:585-589
    • (2010) Cancer Biol Ther , vol.9 , pp. 585-589
    • Mato, A.1    Luger, S.2    Heitjan, D.3
  • 54
    • 35748936767 scopus 로고    scopus 로고
    • Predictive factors of septic shock and mortality in neutropenic patients
    • 10.1080/10245330701384237
    • Jeddi R, Zarrouk M, Benabdennebi Y et al (2007) Predictive factors of septic shock and mortality in neutropenic patients. Hematology 12:543-548
    • (2007) Hematology , vol.12 , pp. 543-548
    • Jeddi, R.1    Zarrouk, M.2    Benabdennebi, Y.3
  • 55
    • 84873238412 scopus 로고    scopus 로고
    • Incidence and impact of baseline electrolyte abnormalities in patients admitted with chemotherapy induced febrile neutropenia
    • 21326626 10.7150/jca.2.62
    • Shaikh AJ, Bawany SA, Masood N et al (2011) Incidence and impact of baseline electrolyte abnormalities in patients admitted with chemotherapy induced febrile neutropenia. J Cancer 2:62-66
    • (2011) J Cancer , vol.2 , pp. 62-66
    • Shaikh, A.J.1    Bawany, S.A.2    Masood, N.3
  • 56
    • 67651204770 scopus 로고    scopus 로고
    • Evaluation of the risk factors for febrile neutropenia associated with hematological malignancy
    • 19554402 10.1007/s10156-009-0683-y
    • Nakagawa Y, Suzuki K, Masaoka T (2009) Evaluation of the risk factors for febrile neutropenia associated with hematological malignancy. J Infect Chemother 15:174-179
    • (2009) J Infect Chemother , vol.15 , pp. 174-179
    • Nakagawa, Y.1    Suzuki, K.2    Masaoka, T.3
  • 57
    • 77649189452 scopus 로고    scopus 로고
    • The suggestion of a risk stratification system for febrile neutropenia in patients with hematologic disease
    • 19762083 10.1016/j.leukres.2009.08.024
    • Park Y, Kim D, Park S et al (2010) The suggestion of a risk stratification system for febrile neutropenia in patients with hematologic disease. Leuk Res 34:294-300
    • (2010) Leuk Res , vol.34 , pp. 294-300
    • Park, Y.1    Kim, D.2    Park, S.3
  • 58
    • 44949102248 scopus 로고    scopus 로고
    • Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients
    • 10.1007/s00520-007-0347-3
    • De Souza VL, Serufo JC, da Costa Rocha MO et al (2008) Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer 16:841-846
    • (2008) Support Care Cancer , vol.16 , pp. 841-846
    • De Souza, V.L.1    Serufo, J.C.2    Da Costa Rocha, M.O.3
  • 59
    • 83255184514 scopus 로고    scopus 로고
    • Clinical factors predicting bacteremia in low-risk febrile neutropenia after anti-cancer chemotherapy
    • 10.1007/s00520-010-1017-4
    • Eun Ha Y, Song JH, Kang WK et al (2011) Clinical factors predicting bacteremia in low-risk febrile neutropenia after anti-cancer chemotherapy. Support Care Cancer 19:1761-1767
    • (2011) Support Care Cancer , vol.19 , pp. 1761-1767
    • Eun Ha, Y.1    Song, J.H.2    Kang, W.K.3
  • 60
    • 77957815662 scopus 로고    scopus 로고
    • Multiplex blood PCR in combination with blood cultures for improvement of microbiological documentation of infection in febrile neutropenia
    • 20720024 10.1128/JCM.00147-10 1:STN:280:DC%2BC3cfmsFGhtA%3D%3D
    • Lamoth F, Jaton K, Prod'hom G et al (2010) Multiplex blood PCR in combination with blood cultures for improvement of microbiological documentation of infection in febrile neutropenia. J Clin Microbiol 48:3510-3516
    • (2010) J Clin Microbiol , vol.48 , pp. 3510-3516
    • Lamoth, F.1    Jaton, K.2    Prod'Hom, G.3
  • 61
    • 80052088844 scopus 로고    scopus 로고
    • High pentraxin 3 level predicts septic shock and bacteremia at the onset of febrile neutropenia after intensive chemotherapy of hematologic patients
    • 21880642 10.3324/haematol.2011.044925
    • Vänskä M, Koivula I, Hämäläinen S et al (2011) High pentraxin 3 level predicts septic shock and bacteremia at the onset of febrile neutropenia after intensive chemotherapy of hematologic patients. Haematologica 96:1385-1389
    • (2011) Haematologica , vol.96 , pp. 1385-1389
    • Vänskä, M.1    Koivula, I.2    Hämäläinen, S.3
  • 62
    • 79955430154 scopus 로고    scopus 로고
    • Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy
    • 21509769 10.1002/cncr.25691
    • Lyman G, Kuderer N, Crawford B et al (2011) Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 117:1917-1927
    • (2011) Cancer , vol.117 , pp. 1917-1927
    • Lyman, G.1    Kuderer, N.2    Crawford, B.3
  • 63
    • 61649126029 scopus 로고    scopus 로고
    • A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies
    • 19139177 10.1093/annonc/mdn655 1:STN:280:DC%2BD1M7mvVOmsw%3D%3D
    • Moreau M, Klasterky J, Schwarzbold A et al (2009) A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies. Ann Oncol 20:513-519
    • (2009) Ann Oncol , vol.20 , pp. 513-519
    • Moreau, M.1    Klasterky, J.2    Schwarzbold, A.3
  • 64
    • 33644678723 scopus 로고    scopus 로고
    • Can we predict the duration of chemotherapy-induced neutropenia in febrile neutropenic patients, focusing on regimen-specific risk factors? A retrospective analysis
    • 16322116 10.1093/annonc/mdj092 1:STN:280:DC%2BD287ht1Oktg%3D%3D
    • Lalami Y, Paesmans M, Muanza F et al (2006) Can we predict the duration of chemotherapy-induced neutropenia in febrile neutropenic patients, focusing on regimen-specific risk factors? A retrospective analysis. Ann Oncol 17:507-514
    • (2006) Ann Oncol , vol.17 , pp. 507-514
    • Lalami, Y.1    Paesmans, M.2    Muanza, F.3
  • 65
    • 33748974393 scopus 로고    scopus 로고
    • EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumors
    • 16750358 10.1016/j.ejca.2006.05.002 1:CAS:528:DC%2BD28XhtVagtrbL
    • Aapro MS, Cameron DA, Pettengell R et al (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumors. Eur J Cancer 42:2433-2453
    • (2006) Eur J Cancer , vol.42 , pp. 2433-2453
    • Aapro, M.S.1    Cameron, D.A.2    Pettengell, R.3
  • 66
    • 74549210268 scopus 로고    scopus 로고
    • Advances in the treatment of neutropenia
    • 19550332 10.1097/SPC.0b013e32832ea6ae
    • Dale C (2009) Advances in the treatment of neutropenia. Curr Opin Support Palliat Care 3:207-212
    • (2009) Curr Opin Support Palliat Care , vol.3 , pp. 207-212
    • Dale, C.1
  • 67
    • 80053173427 scopus 로고    scopus 로고
    • Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: Systematic review and meta-analysis
    • 21943360 10.1186/1471-2407-11-404 1:CAS:528:DC%2BC3MXhtlamu7vJ
    • Cooper K, Madan J, Whyte S et al (2011) Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 11:404
    • (2011) BMC Cancer , vol.11 , pp. 404
    • Cooper, K.1    Madan, J.2    Whyte, S.3
  • 68
    • 84879687663 scopus 로고    scopus 로고
    • Febrile neutropenia (FN) in patients with solid tumors (St): Is the risk of complications affected by the type of chemotherapy?
    • Klastersky J, Georgala A, Ameye L et al (2010) Febrile neutropenia (FN) in patients with solid tumors (St): is the risk of complications affected by the type of chemotherapy? Support Care Cancer 18:S67-S220
    • (2010) Support Care Cancer , vol.18
    • Klastersky, J.1    Georgala, A.2    Ameye, L.3
  • 69
    • 67650309542 scopus 로고    scopus 로고
    • Should the indications for the use of myeloid growth factors for the prevention of febrile neutropenia in cancer patients be extended?
    • 19509500 10.1097/CCO.0b013e32832c9651 1:CAS:528:DC%2BD1MXnsVeiurw%3D
    • Klastersky J, Awada A, Aoun M et al (2009) Should the indications for the use of myeloid growth factors for the prevention of febrile neutropenia in cancer patients be extended? Curr Opin Oncol 21:297-302
    • (2009) Curr Opin Oncol , vol.21 , pp. 297-302
    • Klastersky, J.1    Awada, A.2    Aoun, M.3
  • 70
    • 27244449783 scopus 로고    scopus 로고
    • Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide
    • 16129844 10.1200/JCO.2005.03.099 1:CAS:528:DC%2BD2MXhtFCrsbrE
    • Papaldo P, López M, Marolla P et al (2005) Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol 23:6908-6918
    • (2005) J Clin Oncol , vol.23 , pp. 6908-6918
    • Papaldo, P.1    López, M.2    Marolla, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.